November 7, 2022



News
March 28, 2022
Navrogen Presents Preclinical Data on Its NAV-001 Antibody-Drug Conjugate Program at the 12th World ADC Conference in London
November 30, 2021
Navrogen Announces Publication of its Block-Removed Immunoglobulin Technology (BRITE) to Optimize Rituximab Activity in Humoral Immunosuppressed Cancers
September 13, 2021
Navrogen Enters into CRADA with USAMRIID to Test Proprietary Small Molecule NK Cell Activators Against SARS-COV-2 Infection
August 17, 2021
Navrogen Inc. and Tavotek Biotherapeutics Announce Strategic Collaboration to Improve Therapeutic Efficacy of Antibody Pipeline Agents
August 9, 2021
Navrogen Closes $3.0M Seed Financing to Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers and Immune-Related Disorders
July 1, 2021
Navrogen Signs Commercial Evaluation License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immunosuppressed Cancers
January 11, 2021
Navrogen Establishes Research Collaboration with The National Cancer Institute to Test Mesothelin-Targeting Therapies for Cancers Affected by Humoral Immuno-Oncology Factors
September 29, 2020
Navrogen Signs Commercial License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immuno-suppressed Cancers
September 14, 2020